Innovative Approaches in the Treatment and Management of Hereditary Angioedema (HAE): Key Considerations in Managed Care Decision-Making

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
BioCryst and Takeda Pharmaceuticals USA, Inc.

Hereditary angioedema (HAE) is a rare autosomal dominant condition characterized by recurrent attacks of edema at different locations of the body. This potentially life-threatening disease affects approximately 1 in 67,000 individuals, with no identified differences in sex or ethnicity. HAE is characterized by recurrent edema attacks and the cutaneous attacks can be disabling, with the skin, gastrointestinal tract, and upper airways are most commonly affected and with a persistent risk to the patient of acute events of laryngeal swelling that may prove fatal if not treated in a timely manner. Angioedema in general can be confused with cellulitis, Graves disease, blepharochalasis, eosinophilic fasciitis, or amyloidosis which can lead to delays in diagnosis, and inappropriate treatment poses the risk of adverse events, unnecessary surgical interventions, a higher burden of misery, and a potentially higher rate of morbidity and mortality. Fortunately for patients with HAE, novel therapies have recently become available in the past few years that have shown improved efficacy and safety with improved administration methods. Additionally, new monoclonal antibody therapies targeted at younger HAE populations are on the horizon. With these new options comes a knowledge gap among physician medical directors, pharmacists, immunologists and nurse case managers as the treatment paradigm is growing. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm, including throughout formulary and health plan discussions, which will ultimately improve patient outcomes in the HAE patient population.

Upon completion of this activity, participants will be able to:

  • Evaluate the clinical and economic burden of hereditary angioedema (HAE) in terms of drug utilization, adverse event management, and hospitalizations

  • Characterize the diagnosis and background of HAE and the significance of early intervention

  • Assess the safety and efficacy of available and emerging treatment options for HAE including on-demand therapies, short-term prophylaxis, and long-term prophylaxis

  • Analyze the emerging role of monoclonal antibody treatments in younger populations in the management of HAE

  • Review the evolving role of oral therapy in the prevention of HAE attacks

  • Explore the need for individualized treatment and the role of the managed care professional in patient and provider education, especially around younger populations, for effective HAE management


Faculty: William R. Lumry, MD
Clinical Professor of Internal Medicine
University of Texas Southwestern Medical School
Medical Director, AARA Research Center
Private Practice, Allergy and Asthma Specialists of Dallas


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Lumry has served as a consultant for Astria, BioCryst, Biomarin, CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia, Kalvista, Magellan, Optum, Pharming, Pharvaris, and Shire/Takeda. He has served as a speaker for AstraZeneca, BioCryst, CSL Behring, Grifols, GlaxoSmithKline, Optinose, Pharming, Shire/Takeda, and Sanofi/Regeneron. He has received grant/research support from Astria, BioMarin, CSL Behring, Intellia, Grifols, Ionis, Kalvista, and Shire/Takeda. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
BioCryst and Takeda Pharmaceuticals USA, Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue